[ad_1]
The secret history of the 2018 elections in 84 color pages.
I’ll buy it
Due to a manufacturing defect, the test subjects did not receive the same doses of the pooled AstraZeneca and Oxford University vaccine, making the true efficacy of the vaccine questionable. Experts say it could cost manufacturers a lot because it could undermine the project’s credibility and confidence in the vaccine.
Oxford vaccine developers announced Monday that vaccination prevented 70.4 percent of test subjects from contracting the coronavirus in the third phase of the study. The developers reported that the vaccine worked in different age groups, including the elderly. Seventy percent protection came from a combination of two different tests: Vaccination was 90 percent effective in those who received only half a dose first and then a second. In test subjects who received the full dose for the first time, the vaccine was only 62 percent effective.
However, it was later revealed that some of the testers had given half the dose to some of the testers, not intentionally, but due to a manufacturing defect, and while AstraZeneca said it was a lucky coincidence, it turned out to be a method. more effective dosage. project credit. The lowest dose was received for less, 2,800, while the double full dose was received for 8,900.
Additionally, Moncef Slaoui, head of funding for vaccine development in the United States called Operation Warp Speed, said that these 2,800 people were all under the age of 55, so it is unknown how members of the particularly vulnerable older age group , they would have responded to the vaccine.
However, this information was not included in the original communication from AstraZeneca.
It can also be problematic that the manufacturer has combined the results of two different clinical trials. The vaccine is also being tested in the UK and Brazil, but the subjects have not been vaccinated with the same placebo in the two countries.
Hungary has immobilized 6.5 million units of the Oxford vaccine, which is equivalent to 3,270,000 doses, since one person needs two vaccines. Compared to its more efficient competitors, it can have the advantage of being economical and being able to be stored for a long time at lower temperatures.
AstraZeneca would compare the half-dose and full-dose vaccination protocol discovered as a result of the error with thousands of participants in global trials.
(New York Times, telex)
[ad_2]
